Longeveron LLC (LGVN) is a Healthcare · Biotechnology company listed on NASDAQ. Price $2.44 (-9.96%), Market cap $0.02B, 52-week low–high $0.48 ~ $1.74.
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.
Financial statements, price targets, institutional (13F) holdings and related news for Longeveron LLC are updated in real time on BlackAll Trade.
Longeveron LLC trades at $2.44 (-9.96%). Real-time quotes and charts are available on BlackAll Trade.
Longeveron LLC has a market cap of about $0.02B.
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOM